Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors

Fineline Cube Apr 14, 2026
Company Deals

Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M

Fineline Cube Apr 14, 2026
Company Deals

Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration

Fineline Cube Apr 14, 2026
Company Deals

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Fineline Cube Apr 13, 2026
Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History

Fineline Cube Apr 14, 2026
Company Drug

Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years

Fineline Cube Apr 14, 2026
Company Drug

Roche’s CT-388 Shows Significant Weight Loss in Phase I Clinical Trial for Obesity

Fineline Cube May 20, 2024

Switzerland-based healthcare giant Roche (SWX: ROG) has announced preliminary results from a Phase I study...

Company Deals

Biocytogen Expands Reach to India with GVSAP Partnership for BioMice Models

Fineline Cube May 20, 2024

A recent stock exchange announcement from China-based Biocytogen (HKG: 2315) has highlighted a strategic partnership...

Company

HutchMed Chairman Simon To Steps Down, Dr. Dan Eldar Appointed Successor

Fineline Cube May 20, 2024

HutchMed (NASDAQ: HCM, HKG: 0013) today announced a significant change in leadership with the long-serving...

Company Drug

Eisai to Support Grassroots Healthcare in China with Significant Pariet Donation

Fineline Cube May 20, 2024

Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced its commitment to donate 100,000...

Company Drug

North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China

Fineline Cube May 17, 2024

North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from...

Company Drug

HutchMed’s Sovleplenib Phase III Results to be Showcased at EHA 2024

Fineline Cube May 17, 2024

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013), a biopharmaceutical company based in China, is preparing...

Company Drug

Shanghai UniCAR-Therapy’s Innovative CAR-T Therapy Targets Breakthrough Designation with IL-6 Silencing

Fineline Cube May 17, 2024

Shanghai UniCAR-Therapy Bio-Medicine Technology Co., Ltd, a leading biopharmaceutical company based in China, is on...

Company Deals

Sol-Gel Technologies Partners with Shenzhen Beimei for Twyneo Commercialization in China

Fineline Cube May 17, 2024

Israel-based dermatology specialist Sol-Gel Technologies Ltd. (NASDAQ: SLGL) has announced the signing of a licensing...

Company Deals

J&J Acquires Immune-Mediated Diseases Specialist Proteologix in a Deal Worth Up to USD 850 Million

Fineline Cube May 17, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has announced a deal to...

Policy / Regulatory

China’s Health Commission Boosts Efforts to Monitor and Respond to Drug Shortages

Fineline Cube May 17, 2024

The National Health Commission (NHC) of China has recently announced the reinforcement of national and...

Company Deals

Huaixi Medical and Beijing HumaDX Tech Join Forces to Boost In Vitro Diagnostics

Fineline Cube May 17, 2024

Huaixi Medical, a Nanjing-based specialist in flow cytometry, has entered into a strategic partnership with...

Company Drug

Bayer’s 225Ac-PSMA-Trillium Therapy Begins Early-Stage Clinical Trial for mCRPC

Fineline Cube May 17, 2024

Bayer AG (ETR: BAYN), a multinational pharmaceutical company based in Germany, has this week commenced...

Company Deals

Merck KGaA Subsidiary Teams Up with Aulos Bioscience to Test PD-L1 and Anti-IL-2 Combination

Fineline Cube May 17, 2024

Germany’s Merck KGaA (ETR: MRK) has announced that its Switzerland-based subsidiary, Ares Trading, has entered...

Company Medical Device

Chunlizhengda’s Handheld Orthopedic Robot Approved by China’s NMPA

Fineline Cube May 17, 2024

Beijing Chunlizhengda Medical Instruments Co., Ltd (HKG: 1858, SHA: 688236) has received marketing approval from...

Company

Roche Marks 30 Years in China with Commitment to Boost Investments and Local Manufacturing

Fineline Cube May 17, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has reaffirmed its long-term commitment to the Chinese...

Company Deals

Hengrui Pharmaceuticals Strikes Deal with Hercules CM Newco to Supply GLP-1 Products for Global Markets

Fineline Cube May 17, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has entered into...

Company Drug

Roc Rock Biotechnology Secures Ethical Approval for CAR-M Therapy in Ovarian Cancer

Fineline Cube May 16, 2024

China-based Roc Rock Biotechnology Co., Ltd. has announced that it has received ethical approval from...

Policy / Regulatory

Landmark Biosecure Act Passes US House Committee with 40-1 Vote, Eyes 2024 Enactment

Fineline Cube May 16, 2024

The US House Committee on Oversight and Accountability has completed the markup process for amendments...

Company Deals

Novo Holdings Gains Controlling Interest in Biopharma Equipment Supplier Single Use Support

Fineline Cube May 16, 2024

Novo Nordisk’s (CPH: NOVO-B) controlling shareholder, Novo Holdings, has entered into an agreement to purchase...

Company Deals

AstraZeneca and BenevolentAI Reach Milestone in Heart Failure Target Validation

Fineline Cube May 16, 2024

AstraZeneca (AZ; NASDAQ: AZN) has announced the successful experimental validation of a groundbreaking heart failure...

Posts pagination

1 … 343 344 345 … 650

Recent updates

  • GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors
  • Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M
  • Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration
  • Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History
  • Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors

Company Deals

Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M

Company Deals

Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration

Company Drug

Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.